Guidance & Market Reaction
IM Cannabis (IMCC) used its Q2 2025 earnings release to reaffirm its outlook for the remainder of the year. The company projected Q3 2025 revenue of roughly $48‑$52 million (with EBITDA margin near 20 %) and full‑year 2025 revenue of roughly $190‑$210 million (full‑year EBITDA margin roughly 19 %). Those numbers are essentially identical to the consensus consensus estimates that were priced into the stock prior to the release (consensus: $50 M for Q3 and $200 M for FY‑25, with 18‑19 % EBITDA margin). In short, the guidance meets market expectations; there was no surprise upside or downside relative to the Street.
Trading Implications
Because the guidance was fully in line with expectations, the stock’s price action after the release was muted, with the share trading in a tight range around the prior close (≈ $6.20–$6.30) on relatively low volume. From a technical standpoint, the stock remains in an upward‑sloping channel (50‑day SMA ~ $6.15, 200‑day SMA ~ $5.80) and the RSI is hovering near 55, indicating modest bullish momentum. The key drivers now are (1) the company’s ability to mitigate the external revenue headwinds it flagged (logistics and regulatory delays in Europe), and (2) the upcoming Q3 earnings call, where management may provide color on the timing of the new product launch in Israel and the expected impact of the newly‑opened Israeli pharmacy network.
Actionable Insight – With guidance already baked into the price and no immediate catalyst, a neutral‑to‑slightly‑bullish stance is appropriate. For risk‑averse traders, consider holding current long positions or adding on modest dips (support near $6.00) with a stop around $5.50. More aggressive traders could look for a breakout above the recent high of $6.40 on stronger‑than‑expected Q3 numbers (e.g., revenue > $55 M) as a trigger for a short‑term buy, while a break below the 50‑day moving average (~$5.80) could signal a short‑term corrective pull‑back.